Triptolide exerts an anti-tumor effect on non-small cell lung cancer cells by inhibiting activation of the IL-6/STAT3 axis

YING HUANG, ZHE CHEN, YU WANG, XIN BA, YAO HUANG, PAN SHEN, HUI WANG and SHENGHAO TU

Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China

Received November 7, 2018; Accepted April 23, 2019

DOI: 10.3892/ijmm.2019.4197

Abstract. Lung cancer is the leading cause of cancer-associated mortality and current treatments are not sufficiently effective. Numerous studies have revealed that triptolide (TP), a classical traditional Chinese medicine compound widely used as an anti-inflammatory and antirheumatic drug, also has an antitumor effect. This effect is hypothesized to be mediated by multiple pathways, with signal transducer and activator of transcription 3 (STAT3) possibly one of them. Evidence indicates that STAT3 participates in the initiation and progression of lung cancer during cell proliferation, apoptosis and migration; however, whether and how TP affects STAT3 and its targets remain unclear. In this study, the potential role of TP in the proliferation, apoptosis, and migration of non-small cell lung cancer cell lines was investigated and evaluated the impact of TP on the interleukin-6 (IL-6)/STAT3 axis. The results showed that TP inhibited cell proliferation and migration and induced apoptosis. TP decreased the phosphorylation of STAT3, inhibited STAT3 translocation into the nucleus, and reduced the expression of STAT3 target genes involved in cell survival, apoptosis and migration, e.g. C-myc, BCL-2, myeloid cell leukemia-1 (MCL-1), and matrix metallopeptidase 9 (MMP-9). Additionally, IL-6-induced activation of STAT3 target genes (e.g. MCL-1 and BCL-2) was attenuated by TP and homoharringtonine. In conclusion, the effect of TP on STAT3 signaling points to a promising strategy for drug development.

Introduction

Lung cancer is the leading cause of cancer-related deaths worldwide, imposing a heavy social and economic burden in China (1). Non-small cell lung cancer (NSCLC) accounts for ~85% of lung cancer histological subtypes (2). The majority of NSCLC cases are diagnosed at an advance stage (~70%), with patients missing the chance for radical surgery and thus facing chemotherapy as the main treatment option (3). Despite the excitement after the shift from empirical therapy to more effective and better tolerated regimens for NSCLC over the past two decades, the 5-year overall survival rate remains as low as 4-17% depending on the stage and regional differences (4). What makes the situation worse is that among patients with NSCLC, after a transient response to initial treatment, drug resistance of malignant cells occurs frequently. Therefore, finding an effective and safe anti-tumour agent is one of the highest-priority goals in lung cancer research.

Signal transducer and activator of transcription 3 (STAT3) is an important member of the STAT family and is recognised as a key oncogenic factor highly relevant to NSCLC (5). STAT3 plays crucial roles in cancer initiation and progression by binding to the promoter regions of a number of genes that encode regulators of cell proliferation (such as cyclin D1 and MYC), survival (such as BCL-2 and myeloid cell leukemia-1 (MCL-1)), inflammation (such as interleukin-6 (IL-6) and cyclooxygenase-2), and metastasis (such as matrix metalloproteinase 9 (MMP-9) and vimentin) (6-8). STAT3 activation is transient and dynamic under physiological conditions. However, activated STAT3 is persistently present in 50% of NSCLC tissue (9) due to stimulation of an upstream signaling pathway (10), suggesting that STAT3 is a lung cancer-specific target for anticancer therapy. Activation of cell cycle and survival genes enables STAT3-expressing cells to escape damage from conventional chemotherapeutic drugs (11); thus, the STAT3 oncogenic pathway is involved in drug resistance (12). Similarly, a meta-analysis has revealed that (13) expression of STAT3 or phosphorylated STAT3 (p-STAT3) is a strong predictor of poor prognosis among patients with NSCLC (14). Hence, interference with the STAT3 pathway might counteract the resistance to chemotherapy and exert an adjuvant effect during the treatment of lung cancer.

Because current standard treatments are far from ideal for patients with NSCLC, a natural compound with multiple advantages has come to our attention (15). Triptolide (TP), a classical natural compound, has been demonstrated to exert anti-tumour effects on ovarian cancer (16), breast cancer (17), hepatocellular carcinoma (18) and lung cancer (19). Studies have revealed that low-dose TP helps to circumvent resistance,
enhances effectiveness and relieves adverse effects of anti-cancer therapies (20,21). It has been reported that TP exerts its anti-tumour activities in terms of cell proliferation, cell death, angiogenesis, and metastasis (22). Nevertheless, at present, the potential influence of TP on IL-6/STAT3 signalling in NSCLC is still unknown.

In this study, we determined the effect of TP on the proliferation, apoptosis, and invasiveness of NSCLC cells and investigated the potential underlying mechanisms by evaluating low dose TP's influence on the IL-6/STAT axis.

Materials and methods

Materials. TP (>98% purity) was purchased from Dalian Meilun Co., Ltd. Human recombinant IL-6 (cat. no. 200-06; Peprotech, Inc.) was resolved and stored according to the manufacturer's instructions. 3-(4,5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) and protease inhibitor cocktail (cat. no. 04693132001) were purchased from Sigma-Aldrich (Merck KGaA). Antibodies against anti-cleaved caspase-3 (cat. no. GB11009) were purchased from Servicebio. Antibodies against B cL-2 (cat. no. 182858) and MMP -9 (cat. no. 76003) were purchased from Abcam, McL-1 (cat. no. 94296), cyclin d 1 (cat. no. 2978S), c- myc (cat. no. 2939S), c- myc (cat. no. 4904) and p-STAT3 (cat. no. 9145) were acquired from Cell Signaling Technology Inc., and antibodies against β-actin (cat. no. BB0710) were from Biossci Biotechnology Co., Ltd. DAPI, Triton X-100 and an anti-fade mounting medium were purchased from Servicebio. The Annexin V/PI Apoptosis Detection kit (cat. no. KGA105-KGA108) was from Nanjing KeyGen Biotech Co., Ltd. Propidium iodide (PI) and the Jc-1 Staining kit were acquired from Beyotime Institute of Biotechnology. DyLight 488-conjugated goat anti-rabbit IgG antibody (cat. no. A24221) was from Abbkine Scientific Co., Ltd.

Cell culture. Human lung adenocarcinoma PC9 cells sensitive to epidermal growth factor receptor (EGFR) with low expression of IL-6 and human alveolar basal epithelial adenocarcinoma A549 cells with higher expression of IL-6 were provided by the Caner Laboratory, Tongji Medical College (Wuhan, China). The cells were cultured in RPMI-1640 medium (HyClone; GE Healthcare Life Sciences) supplemented with 10% FBS and 1% penicillin and streptomycin at 37°C in a humidified incubator with 5% CO2 and 95% air.

MTT assay. Cells were seeded in 96-well plates at a density of 5x10^4 cells per well and cultured overnight. A series of concentrations ranging to 500 nM TP were added into the medium. After either 24 or 48 h, MTT was added to assay cell viability. Absorbance at 570 nm was recorded on a microplate reader (Synergy 2; BioTek Instruments, Inc.). The inhibition ratio was calculated as 1-optical density (OD)_{treated}/OD_{control}. The IC_{50} values were calculated by plotting the drug concentration versus the percent cell viability of the cells after TP intervention for 24 and 48 h.

Flow cytometry. At 3x10^5 cells per well were exposed to TP in 12 wells for 24 h after overnight serum starvation. Thereafter, the cells were washed with PBS and fixed with 70% ethanol at 4°C overnight. Then, cell cycle analyses were performed through flow cytometry according to the manufacturer's instructions (Beyotime Institute of Biotechnology). Apoptosis was analyzed via pre-treatment with a selected concentration of TP for 24 h (PC9 cells) or 48 h (A549 cells) and then was detected with the Annexin V/PI Staining kit (Nanjing KeyGen Biotech Co., Ltd.) and assayed by flow cytometry (BD FACS Calibur; BD Biosciences). Cells undergoing early-stage apoptosis were categorized as Annexin V+/PI-, whereas Annexin V+/PI+ cells were assumed to be at a late stage of apoptosis. Subsequently, mitochondrial trans-membrane potential (ΔΨ) was determined according to the manufacturer's instructions using the JC-1 Apoptosis Detection kit (Beyotime Institute of Biotechnology). Data analysis was conducted using the FlowJo software (v10.6; FlowJo LLC).

Transwell assay. Transwell migration assays were performed using 24-well Transwell inserts (8 µm pore size; Costar; Corning, Inc.), as described previously (23). A total of 1x10^5 cells were pre-treated with TP for 24 h, then harvested and resuspended in RPMI-1640 (HyClone; GE Healthcare Life Sciences) at a concentration of 10^5 cells/ml. Next, 200 µl of the cell suspension mixed with 750 µl RPMI-1640 medium supplemented with 10% FBS was added to the upper chamber, and incubated for another 24 h at 37°C. Non-migratory cells were gently wiped from the top surface of the membrane with a cotton swab. Migratory cells on the bottom side of the membrane were rinsed with PBS, fixed in 4% paraformaldehyde and stained with 0.1% (m/v) crystal violet for 10 min at room temperature. Images were captured under a LEICA digital microscope (magnification x100; Carl Zeiss AG). The migration rate was quantified by counting the stained cells in selected 3-5 fields of view.

Western blotting. Cells were treated with or without TP for 24 h, then cells were washed twice with ice-cold PBS and lysed in RIPA buffer containing a protease inhibitor cocktail (Thermo Fisher Scientific, Inc.). Soluble proteins were collected after centrifugation at 12,000 x g for 15 min at 4°C. Protein concentration was determined by the bicinechonic acid (BCA) method. Subsequently, 50 µg of each protein sample was separated by SDS-PAGE on a 10-12% gel (120 V, 90 min) and transferred to a PVDF membrane (Bio-Rad Laboratories, Inc.). A total of 50 µg of each protein sample was separated by SDS-PAGE on a 10-12% gel (120 V, 90 min) and transferred to a PVDF membrane (Bio-Rad Laboratories, Inc.) at 280 mA for 90 min. After blocking with 5% non-fat milk for 1 h at room temperature, the membranes were incubated with primary antibodies (1:1,000) at 4°C overnight. After three washes with TBS containing 0.1% Tween 20, the membranes were incubated with fluorescently-labeled secondary antibodies (1:20,000) for 1 h at room temperature. The bands were visualized using a near-infrared fluorescence imaging system (Odyssey; LI-COR Biosciences). Band densities were quantified in the ImageJ software (version 1.52 National Institutes of Health). In addition, cells were pretreated with TP or homoharringtonine (HHT) for 24 h, then 50 nM IL-6 (cat. no. 200-06; PeproTech, Inc.) was added for another 30 min, finally cells were harvested and lysed for western blotting.

Immunofluorescence. Cells (10^5 cells/well) were seeded on glass cover slides. After treatment with 60 nM TP or 4 µM
STAT3 inhibitor for 24 h, the cells were fixed with 4% buffered formalin for 30 min at room temperature, permeabilized with 0.5% Triton X-100, and blocked with 10% goat serum in PBS (Servicebio) for 30 min at room temperature. After successive incubation with the primary antibody (1:100) at 4˚C for 12 h, a secondary antibody (DyLight 488-conjugated goat anti-rabbit IgG; 1:8,000) was incubated for another 1 h at room temperature, at last cells were stained with DAPI (1:500) in the dark for 5 min. The fluorescence signals were captured using a fluorescence microscope (Nikon Eclipse CI; Nikon Corporation).

Statistical analysis. All experiments were conducted in triplicate and repeated three times. Representative results are shown as the mean ± SD and were plotted using Prism 6.0 (GraphPad Software, Inc.). Statistical calculations were performed via one-way ANOVA followed by the Student-Newman-Keuls test. P<0.05 was considered to indicate a statistically significant difference.

Results
TP impairs viability of NSCLC cells by inducing cell cycle arrest. To evaluate the cytotoxic action of TP, PC9 and A549 cells were treated with a series of TP concentrations ranging from 0 to 500 nM for either 24 or 48 h. The IC₅₀ was calculated using log formula. The IC₅₀ of PC9 and was 1,238±243.8 nM and the IC₅₀ of A549 was 1,339±150.2 nM. After 48 h of treatment with TP, the corresponding values were 29.33±2.102 and 135.9±0.9328 nM. As shown in Fig. 1A, TP was cytotoxic.
Figure 2. TP disrupts active mitochondria and induces apoptosis in non-small cell lung cancer cells. (A) PC9 were treated with TP at selected concentration 30, 60 and 90 nM or without TP (control) for 24 h, and A549 were treated with 30, 60 and 120 nM for 48 h, and cells were harvested and apoptosis was detected. Early apoptotic cells were Annexin V+/PI–, and late apoptotic cells were Annexin V+/PI+. (B) The number of apoptotic cells (second quadrant and fourth quadrant which showed Annexin V+) were significantly increased after TP treatment compared with the control group. (C and D) Mitochondrial membrane potential assay was performed using JC-1. When the cell membrane potential is lowered, a transition from red fluorescence to blue fluorescence is detected. The cells under the horizontal gate were indicate reduced mitochondrial membrane potential. Statistical results are expressed as the mean ± SD. *P<0.05 vs. control. TP, triptolide; PI, propidium iodide.
after 48 h treatment even at a low concentrations (P<0.05). TP inhibited proliferation (according to an inhibition ratio) of PC9 and A549 cells at 48 h in a dose-dependent manner. During the 24 h treatment, TP at concentrations <15.625 nM was not cytotoxic at all toward PC9 and A549 cells. The inhibition of proliferation started to be noticeable via a sharp slope in the inhibition ratio (15.625-62.500 nM in PC9 cells and 15.625-125.000 nM in A549 cells) (24) followed by a relatively flat plateau at high TP concentrations. Therefore, these comparatively low doses were selected to conduct subsequent experiments.

Whether TP influences cell viability by affecting the cell cycle was examined (Fig. 1B). On the basis of the inhibition ratio, two concentrations within the sharp-slope region (30 and 60 nM) and one concentration in the plateau region (90 nM, PC-9; 120 nM, A549) were selected. As shown in Fig. 1C, TP at the concentration in the sharp-slope region (30 and 60 nM) strongly promoted the G1/S arrest in PC9 cells. There was a slight increase in the number of cells in the S phase at 90 nM TP as well, but the change was not statistically significant. Similar results were not seen in corresponding experiments on A549 cells after treatment with TP for 24 h. A slight decrease in the number of cells in the S phase at 120 nM TP was observed, though it appeared that TP in general did not affect the cell cycle in A549 cells (Fig. 1C).

TP disrupts active mitochondria and induces apoptosis in NSCLC cells. It was subsequently analyzed whether TP treatment has any impact on apoptosis. Starting from the concentration of 60 nM, treatment of PC9 cells with TP for 24 h caused a significant increase in total apoptosis (Fig. 2A and B). In contrast, after 48 h treatment of A549 cells with TP, total apoptosis increased strongly, and this change was attributed to a late-apoptosis population (Fig. 2A and B). Then, ΔΨ was measured as disruption of mitochondria is regarded as a distinctive feature of the intrinsic pathway of apoptosis. As demonstrated by the JC-1 blue ratio, treatment with TP for 24 h slightly decreased ΔΨ (Fig. 2C and D). These results suggested that TP induced apoptosis at least partially at an early stage by disrupting active mitochondria.

TP inhibits migration of NSCLC cells. Considering the anti-metastasis effect of TP, we an in vitro chamber migration assay was performed to test whether TP affects NSCLC cell migration. As presented in Fig. 3, the number of migratory PC9 cells was decreased by TP treatment and dropped dramatically at 60 and 90 nM; whereas the number of migratory A549 cells stayed largely unchanged upon TP treatment; however, a statistically significant decrease in the number of migratory cells was observed after treatment with 60 and 120 nM TP, but this was less dramatic than the effect in PC9 cells.

TP disturbs an activated STAT3 pathway in NSCLC cells. Aberrant and constitutive activation of STAT3 in NSCLC has been reported (9) and is associated with tumor progression and a poor prognosis (14). After treatment with TP for 24 h, p-STAT3 was decreased in PC9 (Fig. 4A) and A549 cells (Fig. 4B). The mRNA expression of PC9 (Fig. S1) and A549 (Fig. S2) was consistent with protein expression. As shown in Fig. S3, the ratio of p-STAT3/total STAT3 was marginally decreased by TP in A549 cells, with statistical significance at 120 nM (P<0.05).
Expression levels of target genes of STAT3 were also examined. C-myc expression was found to greatly decreased upon TP treatment in PC9 (Fig. 4A) and A549 cells (Fig. 4B). Although cyclin D1 was downregulated by TP in PC9 cells (Fig. 4B), cyclin D1 was upregulated by TP treatment in A549 cells (Fig. 4B). The overexpression of cyclin D1 may contribute to resistance to TP (25), as well as cell DNA damage (24). Caspase-3 is a critical executioner of apoptosis, as it is either partially or totally responsible for the proteolytic cleavage of many key proteins, and cleaved caspase-3 is the active form of the protein. As shown in PC9 cells (Fig. 4A), TP increased the level of cleaved caspase-3. Expression of anti-apoptotic proteins MCL-1 and BCL-2 was decreased after TP treatment in a dose-dependent manner in PC9 (Fig. 4A) and A549 cells (Fig. 4B). The two bands of BCL-2 seen in Fig. 4A may be homodimers or poor antibody specificity (26). TP also downregulated MMP-9 expression in a dose-dependent manner in PC9 (Fig. 4A) and A549 cells (Fig. 4B). The above results suggested that TP treatment inhibited cell proliferation, induced apoptosis and inhibited cell migration by suppressing the activation of STAT3.

Signal transduction in the STAT3 pathway, as visualized by STAT3 translocation into the nucleus, was inhibited by TP treatment. Less prevalent and weaker STAT3 staining was observed in cell nuclei in the TP treatment groups (Fig. 5).

**TP attenuated STAT3 activation induced by IL-6.** Elevated IL-6 expression has been observed in many patients with lung cancer (27). A549 cells appear to be much less sensitive to TP compared with PC9 cells, thus it was speculated that the expression of IL-6 in these cells is associated with the results. The effect of TP in the presence of exogenous IL-6 in PC9 cells was analyzed, with a non-specific IL-6/STAT3 inhibitor HHT serving as a positive control, which prevents the initial elongation step of protein synthesis (Fig. 6). Similar to Ham et al (28), IL-6 seems not significantly increase the phosphorylation of STAT3, but did impair the ability of HHT to inhibit STAT3 phosphorylation. IL-6 appeared to induce expression of the STAT3 downstream target gene, BCL-2, but there was no statistical difference (P>0.05). At the same time, TP and HHT could reduce the expression of BCL-2 compared with IL-6-stimulated cells. Compared with the control group, the expression of MCL-1 was significantly increased by exogenous IL-6 (P<0.05). Similar to HHT, pretreated TP can almost completely block MCL-1 expression. Briefly, TP might enhance the effects of chemotherapy by inhibiting IL-6-induced MCL-1 activation.

**Discussion**

Even though treatment of NSCLC has changed dramatically over the past two decades, only modest improvements have been achieved in terms of the patient survival rate (4). Drug resistance and side effects are still obstacles to successful cancer therapy. With the advantages of low toxicity and cost, natural compounds have been regarded as a promising adjuvant therapies for NSCLC (29). Initially prescribed as an anti-inflammatory drug, TP is considered an alternative therapeutic agent for the treatment of a wide range of cancers, such as pancreatic cancer and colon cancer (30), ovarian cancer (31), breast cancer (32), hepatocellular carcinoma (33) and lung cancer (34). A distinct antitumour activity of TP lies in its antagonism of drug resistance (20,31). This beneficial effect might be mediated by changes in ATP-binding cassette transporters (35), induction of apoptosis pathways, increase in tumor suppressors and decrease in oncogenic factors, and interactions with the RNA polymerase II complex (36) by TP. Aside from mitogen-activated protein kinase (32) and Wnt/β-catenin pathways (33), the IL-6/JAK/STAT3 axis (34,37) is also involved in the antitumour activity of TP in cancer types other than lung cancer. However, at present, the influence of TP on IL-6/STAT3 signaling during the treatment of NSCLC is still unclear.

Although the antitumor effect of TP has been described previously, the current study further confirms how low doses of TP exert anticaner effects or adjuvant to chemotherapy in lung cancer through IL-6/STAT3. In this study, the antitumor effects of TP on PC9 and A549 were analyzed. After balancing effectiveness and possible toxicity, appropriate doses were selected to conduct subsequent experiments. TP inhibited cell proliferation, promoted cell apoptosis and cell migration at a comparative dose in PC9 cells, while TP decreased the expression of genes associated apoptosis resistance, such as MCL-1. Studies indicated that MCL-1 is a key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC (38). The direct antitumor effect in PC9 and the adjuvant effect of circumventing resistance in A549 make it superior to other traditional Chinese therapeutic agents. TP exerted antiproliferative action on both NSCLC cell lines. In agreement with other findings (39), the data showed significant S phase cell cycle arrest in PC9 cells. Such S phase arrest
Figure 5. Phosphorylation of STAT3 was detected by immunofluorescence. Cells were treated with or without TP, the nuclear translocation was detected by immunofluorescence. (A) PC9 and (B) A549 was either untreated or treated with different concentrations of TP. Cells were stained with anti-phosphotyrosine 705-STAT3 antibody (red) and counterstained with DAPI (blue), decreased after treatment with different concentrations of TP compared with control. STAT3, signal transducer and activator of transcription 3; TP, triptolide.

Figure 6. TP decreased activation of STAT3 induced by IL-6. (A) Protein expression of p-STAT3, P-STAT3/STAT3, BcL-2, and McL-1 were detected by western blot analysis. (B) ImageJ was used to analyze the intensity of the band. #P<0.05 vs. untreated; *P<0.05 vs. exogenous IL-6 treatment. p-, phosphorylated; STAT3, signal transducer and activator of transcription 3; Mcl-1, myeloid cell leukemia-1; IL-6, interleukin-6; TP, triptolide.
was not significant in A549 cells after treatment with TP for 24 h. Unexpectedly, there was a decrease of DNA synthesis in the cells treated with 120 nM TP; DNA synthesis change might be a consequence of increased apoptosis observed in the same experimental setting. In any case, the weaker effect of TP on cell cycle arrest in A549 cells compared with PC9 cells is worthy of further investigation. C-myc and cyclin D1 are crucial factors that are associated with STAT3 activation and cell proliferation. A decrease in both C-myc expression and cyclin D1 expression was seen in PC9 cells treated with TP; this result echoes the aforementioned findings and further elucidates the TP-induced cell cycle arrest in S phase. In parallel, C-myc was also found to be downregulated by TP in A549 cells, whereas TP elevated the cyclin D1 level in A549 cells. Overexpression cyclin D1 may cause resistance to cytotoxic drugs (40), thus limiting the effects of TP. However, high levels of cyclin D1 prime cells for an enhanced DNA damage response (24), causing sustained cyclin D1-cyclin-dependent kinase activity, leading to inappropriate replication of DNA and chromosomal damage (41,42). This result may be the reason why S phase arrest was barely detectable among TP-treated A549 cells. On the basis of the literature (24,43), it is speculated that TP enhances DNA damage and arrests the cell cycle in the S phase to inhibit cell proliferation.

Bypassing apoptosis is a critical step in carcinogenesis. The apoptosis pathway, as a result, has been a hot target for many anticancer therapies. As many as 22-65% of NSCLC cells aberrantly express apoptotic proteins; this feature malignantly enhances cell proliferation and promotes resistance to chemotherapy. In this study, TP markedly increased the percentage of cells undergoing early apoptosis in PC9 and A549 cells. Activated caspase-3 is a typical hallmark of apoptosis (44). The findings of the present study showed that TP increases the expression of cleaved caspase-3 in NSCLC cells. Other authors (13,45) have also stated that inhibition of STATs directly decreases the levels of anti-apoptotic proteins, such as Bcl-2 and Mcl-1, which are known to facilitate tumor cell survival. The results of the current study revealed that TP treatment decreased the expression of BCL-2 and MCL-1. Given that TP reduced the phosphorylation of STAT3 in PC9 and A549 cells, it was concluded that TP induces apoptosis of NSCLC cells through the STAT3/MCL-1 axis.

Aberrant activation of STAT3 contributes to cancer progression in human tumors (46). It induces MMP-9, which has an important role in cell invasion and metastasis (47). Activated MMP-9 degrades collagen in the extracellular matrix, and this activity is closely associated with the invasive and metastatic potential of numerous types of solid tumor (48-50). The findings of the current study clearly indicate that TP downregulates MMP-9 expression and inhibits NSCLC cell migration, thus indicating that TP inhibits the STAT3/MMP-9 axis.

The present study demonstrated that TP inhibited cell proliferation and migration, and induced apoptosis by suppressing STAT3 activation and downregulating targets of STAT3. The finding that TP inhibited STAT3 phosphorylation and its nuclear translocation is consistent with data from studies on colitis-related colon cancer (37), multiple myeloma cells (51), and pancreatic cancer (52). The results of the current study show that A549 cells are less responsive to TP, which may be associated with the expression of IL-6 in these cells. NSCLC cells carry mutations in oncogenes Egfr (45%) and Kras (25%) (13); these mutations drive the overexpression of IL-6. Indeed, IL-6 is overexpressed in many patients with lung cancer (27). Hyperactivation of IL-6 could activate STAT3, which in turn produces more IL-6 (5,13,53). In the present study, the influence of TP on STAT3 activation by exogenous IL-6 was analyzed. IL-6 significantly upregulated MCL-1 expression in PC9 cells, and MCL-1 has been demonstrated to be associated with chemoresistance in oral squamous cell carcinoma (54), so IL-6 might be a factor involved in drug resistance. Additionally, IL-6 significantly reduced the ability of HHT to inhibit STAT3 phosphorylation, that is possible reason why A549 showed smaller response to TP than PC9. These data are indicative of a promising application of TP in lung cancer management.

Although appropriate methods have been used to illustrate the hypothesis, it is difficult to demonstrate the exact mechanism of TP against NSCLC. The effect of TP on downstream target genes of STAT3 indicated the possible existence of another regulator, and more research is needed to confirm this conclusion. This preliminary study illustrated that TP has promising effects on NSCLC, a clinical investigation using combined TP with conventional therapy is necessary to determine the effects in recurrent advanced NSCLC. In conclusion, the IL-6/STAT3 pathway appears to be another therapeutic target in NSCLC, and TP may have antitumor effects or at least an adjuvant effect.

Acknowledgements

The authors acknowledge the gift of cells from Tongji Cancer Laboratory.

Funding

This study was supported by the National Natural Science Foundation of China (grant no. 81573802).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

YiH, ZC and ST conceived and designed the study. YiH, YW, XB and YAH performed the experiments. YiH and ST wrote the paper. YiH, ZC and ST reviewed and edited the manuscript. PS and HW provided assistance for data acquisition, statistical analysis and manuscript editing. All authors read and approved the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.
Competing interests

The authors declare that they have no competing interests.

References